These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history of significant losses, which we expect to continue our limited history operating as a commercial company our expectations with respect to the regulatory pathway of our product candidates, our ability to obtain regulatory approvals for such product candidates, and the anticipated effect of delays in obtaining any such regulatory approvals our expectations with respect to preclinical and clinical trial plans for our product candidates, the results of such activities and the safety and efficacy of our product candidates our ability to commercialize our product candidates our ability to compete successfully with larger competitors in our highly competitive industry our ability to achieve and maintain adequate levels of coverage or reimbursement for any future products we may seek to commercialize our expectations regarding our manufacturing capabilities a pandemic, epidemic or outbreak of an infectious disease in the U.S. The forward-looking statements in this press release are only predictions and are based largely on our current business plans, expectations, and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "outlook," "guidance," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
All statements other than statements of historical facts are forward-looking statements, including statements regarding our first ever transplant of a bioengineered liver transplant into a large animal.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information, visit .Ĭautionary Statement Regarding Forward-Looking Statements The Company's initial development focus is on human livers and kidneys. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. Miromatrix's perfusion decellularization and recellularization technology platform includes 119 issued and 34 pending patent applications, with protection in the United States and major markets worldwide. "This important patent demonstrates our ability to revascularize decellularized organs and furthers our commitment to bioengineering completely functional, transplantable organs to solve this major health crisis." "Organ transplantation is one of the largest unmet medical needs facing the world today," says Miromatrix CEO Jeff Ross, Ph.D. Patent Number 11,414,644 is entitled "Methods of Recellularizing a Tissue or Organ for Improved Transplantability." This patent covers the revascularization of decellularized organs and tissues that encompasses all types of organs including liver, lung, kidney, and heart. This new patent further expands the Company's extensive patent portfolio covering the bioengineering of transplantable organs. ( MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, has received a new patent from the United States Patent and Trademark Office for its perfusion decellularization and recellularization technology. 25, 2022 (GLOBE NEWSWIRE) - Miromatrix Medical Inc.
0 kommentar(er)
